Shiro Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shiro Tanaka has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Masataka Shiraki
Research Institute and Practice for Involutional Diseases, Tokyo, Japan
1 shared publicationMitsuru Saito
Department of Orthopaedic Surgery, Jikei University School of Medicine, Tokyo, Japan
1 shared publicationTatsuhiko Kuroda
Public Health Research Foundation, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 19 July 2011
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 26 (11) , 2778-2784
Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women
We investigated whether measurement of pentosidine, in addition to the conventional risk assessment tool, the Fracture and Immobilization Score (FRISC), improves early identification of fracture cases. A total of 765 postmenopausal Japanese women with baseline measurement of urinary pentosidine were followed in a hospital‐based cohort study. Endpoints were incidence of vertebral fracture, incidence of long bone fracture, and incidence of long bone and vertebral fracture. To assess the effect of pentosidine on fracture risk, we fitted multivariate Cox regression models adjusted for age, body weight, diabetes mellitus, lumbar BMD, prior fracture, and presence of back pain. To explore potential nonlinear relationships, we fitted a multivariate generalized additive model. To assess the discriminatory power of pentosidine, we performed receiver operating characteristic analysis. The hazard ratios for a 1 SD increase in pentosidine were 1.18 (95% CI 1.05–1.33, p < 0.01) for vertebral fracture and 1.20 (95% CI 1.07–1.33, p < 0.01) for long bone and vertebral fractures. The relationship was approximately linear, and there was no indication of the presence of a threshold. The C statistics were 0.732 (95% CI 0.686–0.778) for the model with both pentosidine and the 10‐year risk and 0.702 (95% CI 0.654–0.750) for the 10‐year risk alone. Eighty‐three subjects (11%) in the whole cohort were in the highest quartile of pentosidine, although their 10‐year risks were less than 15% and included 17 incident vertebral fracture cases. Urinary pentosidine improves risk classification using conventional risk assessment tools. Optimal clinical strategies of diagnosis and treatment remain uncertain and in need of additional investigation. © 2011 American Society for Bone and Mineral Research
- 19 July 2011
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 26 (11) , 2778-2784
Open AccessUrinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women
We investigated whether measurement of pentosidine, in addition to the conventional risk assessment tool, the Fracture and Immobilization Score (FRISC), improves early identification of fracture cases. A total of 765 postmenopausal Japanese women with baseline measurement of urinary pentosidine were followed in a hospital‐based cohort study. Endpoints were incidence of vertebral fracture, incidence of long bone fracture, and incidence of long bone and vertebral fracture. To assess the effect of pentosidine on fracture risk, we fitted multivariate Cox regression models adjusted for age, body weight, diabetes mellitus, lumbar BMD, prior fracture, and presence of back pain. To explore potential nonlinear relationships, we fitted a multivariate generalized additive model. To assess the discriminatory power of pentosidine, we performed receiver operating characteristic analysis. The hazard ratios for a 1 SD increase in pentosidine were 1.18 (95% CI 1.05–1.33, p < 0.01) for vertebral fracture and 1.20 (95% CI 1.07–1.33, p < 0.01) for long bone and vertebral fractures. The relationship was approximately linear, and there was no indication of the presence of a threshold. The C statistics were 0.732 (95% CI 0.686–0.778) for the model with both pentosidine and the 10‐year risk and 0.702 (95% CI 0.654–0.750) for the 10‐year risk alone. Eighty‐three subjects (11%) in the whole cohort were in the highest quartile of pentosidine, although their 10‐year risks were less than 15% and included 17 incident vertebral fracture cases. Urinary pentosidine improves risk classification using conventional risk assessment tools. Optimal clinical strategies of diagnosis and treatment remain uncertain and in need of additional investigation. © 2011 American Society for Bone and Mineral Research